Report by Horizon Insights
The global market potential for ophthalmic drugs, consumables and devices will exceed US$100bn in the coming years - as a highly innovative company with strong R&D capability Eyebright looks well placed to benefit. Its existing major product lines are: 1) Cataract Intraocular Lens (IOL) - Eyebright’s market share has doubled from 5% in 2018 to 10% in 2021 (without profit margin erosion) and domestic brands are expected to continue to take market share from foreign brands. 2) Orthokeratology Lens (OK Lens) - Eyebright has seen a phenomenal increase in sales having sold 21.5m pieces in 2021 vs. 2.3m pieces in 2019!